Libby is an exploration geologist working to accelerate discovery as the Technical Lead for BHP Xplor. Prior to this she spent five years with BHP Metals Exploration contributing to global exploration strategy through project generation and prospectivity analysis. Libby completed her PhD at McGill University and has since gained experience in different facets of the exploration and mining industry including as a project geologist, researcher and communications specialist. She has experience on varied deposit types across five continents from project generation to resource drilling for companies of all sizes and scopes.
Libby’s eclectic background and personal experiences have fostered an interest in improving the mining industry and making it a more inclusive and appealing sector in which to work. She pursues this through various volunteer roles in industry organisations including the Society of Economic Geologists.
Charlee is the Program Lead for BHP Xplor and oversees/manages the program design and execution focused on connecting participating companies to an ecosystem of internal and external partners. Since joining BHP in 2011, Charlee has held various leadership roles in Onshore Land, Portfolio Strategy & Development and Exploration, most recently serving as the Chief of Staff to the VP Exploration & Appraisal. She started her career with Shell in 2007 after studying Finance and Accounting at The University of Oklahoma. She also has an MBA from The University of Houston.
Aman Khera is Vice President and Global Head of Regulatory Strategy at Worldwide Clinical Trials and has been providing global strategic direction in regulatory affairs for more than two decades. She has built her career on maintaining fastidious patient care with the pragmatism needed to help clients achieve effective regulatory strategies. Aman is available to consult with companies of all sizes, as well as their funding entities, to support their goals – with the primary aim of serving humanity as a whole.
Lisa holds a M.Sc degree in Pharmacy from Uppsala University and has more than 20 years of experience within Clinical Operations, currently working as a Clinical Program Director at Camurus AB in Lund, Sweden. Here she is responsible for the Clinical Development of one of the products in pipeline, currently in Phase 3 in neuroendocrine tumors. She is also partof the Clinical Development management team and responsible for a group of Clinical Trial Managers working on various programs. Prior to joining Camurus in 2019, Lisa worked 10 years at Lundbeck HQ within CNS diseases.
Specialist with outsourcing experience from all aspects of the value chain, from preclinical work and drug manufacturing through to late-stage clinical development activities and post-marketing non-interventional studies. Morten holds over 20 years of industry experience from a number of small- and mid-sized pharma and biotech companies and for the past decade he has been working in GCP and GMP environments with primary focus on handling of outsourcing activities for phase 1-3 clinical program development activities. Morten’s primary roles have included contract negotiation and -execution, as well as vendor management within outsourcing settings, international project- and relationship management as well as follow-up and evaluation of global collaborations within all phases of clinical development.
Matilda Hugerth (born 1975) holds a Master of Pharmaceutical Science from the Uppsala University and is a registered pharmacist. She has more than 20 years drug of development experience from various roles in both large and small pharmaceutical companies including Lundbeck, UCB, Novartis, Abliva and Amniotics. Matilda Hugerth’s expertise includes clinical development strategies with experience from all clinical phases in the areas of regulatory, project management, clinical operations, clinical quality assurance, and medical affairs. Matilda Hugerth is a member of the European Federation of GCP Audit working party and is on the steering committee of Medicon Village’s Regulatory Affairs Network.
Rikke Winther has worked in the CRO and Pharmaceutical industry for the past 30 years and has experience from Clinical R&D, Business Development and Contract/Outsourcing Management. She built up and headed up Lundbeck group of Outsourcing & Contracts Management R&D for 19 years and has for the past 5 years worked as an clinical outsourcing specialist for smaller biopharma and covers CRO selection processes as well as contractual, operational and relationship related activities with clinical CROs.
She has in earlier part of her career within bio-analytical research and clinical development in hospital settings as well as project management and business development management at a clinical CRO in Europe and Asia.
Rikke is a former member of the Steering Committee member of the Pharmaceutical Contract Management Group (PCMG) for many years and is a contributing author of the book: “Outsourcing Clinical Development, Gower Publishing Limited”.
Dr. Caroline Sandström received her PhD in Medical Science from Lund University, Sweden in 2008. She has then worked for Novo Nordisk A/S, Denmark for several years as a pharmacologist driving and executing pharmacological plans supporting pre-clinical projects.
Her interest and enthusiasm for project management, continuous improvement, streamlining initiatives and training was then later beneficially used when she moved into the compliance area managing global improvement and training initiatives within R&D Quality Management System (QMS) including Clinical. For example, she was the project manager for implementing the effective use of Root Cause Analysis in Clinical Development activities but also being highly involved in initiatives related to Quality Culture. Ferring Pharmaceuticals A/S in Copenhagen, DK. On a daily basis she was involved in discussing, driving compliance and improvement initiatives within both Non-Clinical, Clinical and Pharmacovigilance related activities. She has taken a very active role in contributing to a collaborative and transparent organization where sharing learnings are a main focus area.
From beginning of May 2022, she moved into the position of being Head of the Global Clinical Quality Department being responsible for the QA support of global key stakeholder areas such as Clinical Development, Regulatory Affairs, Pharmacovigilance and Discovery. Her scientifically driven problem-solving skills are used for implementing global cross-functional initiatives, and for supporting and strengthening the harmonization and quality mindset in the organization.
Thought leader in domestic and global macroeconomic, markets and political analysis. During my career I have been a developer of capital market strategies and managed domestic and global fixed income portfolios, created new products, recast analytic direction, and rejuvenated/rebuilt departments. Written analysis has generated appearances in financial media throughout the world. Contributor to WSJ Economist Survey, CNBC FOMC Survey, Blue Chip Financial Forecast. Current volunteer work — Treasurer of the National Academy of Design, where I created the investment policies for their newly funded endowment, and am Chair of the Investment Policy Committee.
